Verici Dx, the UK-based developer of advanced transplant diagnostics, has announced it will hold a general meeting of shareholders to seek approval for a new share issuance. The company, which focuses on RNA-based tests to predict organ rejection, said the move is intended to strengthen its balance sheet and fund ongoing commercialisation efforts.
The proposed issuance would see new ordinary shares created, potentially diluting the stakes of current investors. Verici Dx has not yet specified the exact number of shares or the target amount to be raised, but noted that the funds would be used for working capital and general corporate purposes. The meeting is expected to take place later this month.
Shares in Verici Dx have been under pressure this year, reflecting broader challenges in the small-cap biotech sector. The company's lead product, a test for kidney transplant rejection, is still in the early stages of market adoption. Analysts have noted that while the diagnostic pipeline is promising, cash burn remains a concern for the AIM-listed firm.
Shareholder approval is not guaranteed, as some investors may resist dilution. However, the board has urged support, arguing that the capital injection is essential to achieve near-term milestones. The company has previously raised funds through equity placings and convertible notes.
For UK investors holding Verici Dx shares, the outcome of the vote will be critical. If passed, the issuance could provide the runway needed to advance clinical uptake, but it may also weigh on share price in the short term. The company plans to update the market following the meeting.
Source: Verici Dx regulatory announcement